






  





















































<!DOCTYPE html>
<html xmlns="https://www.w3.org/1999/xhtml" lang='en'>
<head>  
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="content-type" content="text/html; charset=UTF-8" />
    <meta name="robots" content="noindex,nofollow"/>
    <meta name="referrer" content="origin-when-cross-origin"/>
  <title>A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis - Tabular View - ClinicalTrials.gov</title>
    <link href="/ct2/show/record/NCT02016482" rel="canonical"/>
  
  <link rel="shortcut icon" href="/ct2/html/images/favicon.ico" />
  <link rel='apple-touch-icon-precomposed' href='/apple-touch-icon-144x144.png' sizes='144x144'>
  <link rel='apple-touch-icon-precomposed' href='/apple-touch-icon-114x114.png' sizes='114x114'>
  <link rel='apple-touch-icon-precomposed' href='/apple-touch-icon-72x72.png'   sizes='72x72'>
  <link rel='apple-touch-icon-precomposed' href='/apple-touch-icon-precomposed.png' >
  <link rel='apple-touch-icon-precomposed' href='/apple-touch-icon.png' >

  <link rel="stylesheet" type="text/css" href="/ct2/html/ct3/jquery/css/superfish.css" media="screen" />
  <link rel="stylesheet" type="text/css" href="/ct2/html/ct3/jquery/css/superfish-vertical.css" media="screen" />
  <link rel="stylesheet" type="text/css" href="/ct2/html/ct3/css/base.css?v=b4" />
  <link rel="stylesheet" type="text/css" href="/ct2/html/ct3/css/print.css" media="print" />
  <link rel="stylesheet" href="/ct2/html/ct3/css/w3-ct.css" type="text/css" />
  <!--[if lt IE 9]>
	<link rel="stylesheet" href="/ct2/html/ct3/css/w3-ct-oldIE.css" type="text/css" />
  <![endif]-->
  	

     <!--[if lte IE 7]>
           <link href="/ct2/html/ct3/css/target-IE7-and-below.css" rel="stylesheet" type="text/css">
    <![endif]-->

<link href="/ct2/html/ct3/css/trial-record.css?v=b4" rel="stylesheet" type="text/css" />
<link href="/ct2/html/ct3/css/ct2Header.css" rel="stylesheet" type="text/css" />


	<script type="text/javascript" src="/ct2/html/ct3/jquery/js/jquery.min.js?v=1.12.4"></script><noscript></noscript>
	    <script type="text/javascript" src="/ct2/html/ct3/jquery/js/superclick.js"></script><noscript></noscript>
    <script type="text/javascript" src="/ct2/html/ct3/jquery/js/jquery.cookie.js"></script><noscript></noscript>
    <script type="text/javascript" src="/ct2/html/images/frame/ct.js"></script><noscript></noscript>
    <script type="text/javascript" src="/ct2/html/ct3/js/ctmenu.js?v=b4"></script><noscript></noscript>

    <script type="text/javascript" src="/ct2/html/images/foresee/foresee-trigger.js"></script><noscript></noscript>
<script type="text/javascript">
    $(window).load(function(){
        loadCTCommon();
        });
</script>
 


  <script type="text/javascript">
    ncbi_pingWithImage=true;
    __ncbi_stat_url="//www.ncbi.nlm.nih.gov/stat";        
  </script>
  
  <meta name="ncbi_sid" content="861650e6986030b6_93101SID"/>
  <meta name="ncbi_app" content="ctgov"/>
  <meta name="ncbi_db" content="ctgov"/>
  <meta name="ncbi_pdid" content="show_record"/>
  <meta name="ncbi_pcid" content="NCT02016482"/>
  <meta name="ncbi_ctreqid" content="RRe02X5y"/>
  <meta name="ncbi_ctsessid" content="SRe01iI4"/>
  <meta name="ncbi_ctipid" content="IzOkI5NS"/>
  <meta name="ncbi_cthost" content="wp2"/>
</head>

<body class="js one-column"> 
<div id="skip"> <a href="#main-content">Skip to Main Content</a> </div>

<script type="text/javascript">
	var RetractableBannerStateProperty = 'CT_NewsBannerState';
	
	ToggleBanner = function()
    {
        var theAccordion = $('#retractableBanner'); 
       	if (theAccordion.css("display") == "none") {
        		$('#showMore').css('visibility', 'hidden');
        	} else {
         		$('#showMore').css('visibility', 'visible');
        	}
        theAccordion.slideToggle({
            duration: 'fast',
            start: function(){
				            	if (typeof FuncReAlign !== 'undefined') {
            		$( "table.fixedHeader-floating" ).hide();
            	}
			},
            done: function(){
            	if (theAccordion.css("display") == "none") {
            		rememberRetractableBannerState('hide');
            	} else {
            		rememberRetractableBannerState('show');
            	}
            	if (typeof FuncReAlign !== 'undefined') {
                	FuncReAlign();  
            		$( "table.fixedHeader-floating" ).show();
            	}
            }
		});
    };
	    
	var rememberRetractableBannerState = function(newState) {
		try {
			sessionStorage.setItem(RetractableBannerStateProperty, newState);
		} catch (e) {}
	};

	$(window).ready(function(){
		try {
			var retractableBannerState = sessionStorage.getItem(RetractableBannerStateProperty);
					    if (retractableBannerState === null  || retractableBannerState === 'show') {
				ToggleBanner();
			}
		} catch (e) {};
	});
</script><noscript></noscript>
<div class="w3-container w3-center" style="padding:1.5ex 0.125in 0;background:#205493;color:white">
	<div style="font-weight:bold;">This site became the new ClinicalTrials.gov on June 19th. <a href="https://www.nlm.nih.gov/pubs/techbull/mj17/mj17_clinicaltrials_improve_usability.html" style="margin-left:1em;color:white;border-bottom-color:white;">Learn more.</a>
		<div id="showMore" style="float:right;cursor:pointer;border-bottom:1px dotted white;" onclick="ToggleBanner();">Show more <img src="/ct2/html/ct3/images/show-more.png" style="width:17px;"></div>
	</div>
	<div id="retractableBanner" style="margin-top:1ex;display:none;">We will be updating this site in phases. This allows us to move faster and to deliver better services.
		<div id="showLess" style="float:right;cursor:pointer;border-bottom:1px dotted white;" onclick="ToggleBanner();">Show less <img src="/ct2/html/ct3/images/show-less.png" style="width:17px;"></div>
	</div>
</div>
<div id="wrapper" style="padding-top:0;">  <div id="longAlert" class="w3-hide-small" style="background-color:papayawhip;font-size:small;margin-bottom:1.5ex;">
	<img src="/ct2/html/ct3/images/warning.png" alt="ClinicalTrials.gov Menu" style="max-width:0.8rem;cursor:pointer;"/>
    <b>IMPORTANT</b>: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study.  <a href="/ct2/about-site/disclaimer">Read more...</a>
</div>
<div id="shortAlert" class="w3-hide-medium w3-hide-large" style="background-color:papayawhip;font-size:small;margin-bottom:1.5ex;">
	<img src="/ct2/html/ct3/images/warning.png" alt="ClinicalTrials.gov Menu" style="max-width:0.8rem;cursor:pointer;"/>
    <b>IMPORTANT</b>: Talk with a trusted healthcare professional before volunteering for a study. <a href="/ct2/about-site/disclaimer">Read more...</a>
</div>

  
	<div id="header" style="float:left;"> <a href="/ct2/home" style="border-style:none;box-shadow:none;"><img src='/ct2/html/ct3/images/ct.gov-logo.png' alt='ClinicalTrials.gov' style='max-width:100%;' /></a><br />
    	<div id="tagline">A service of the U.S. National Institutes of Health</div>
  	</div>
					<div id="hamburger" class="w3-hide-medium w3-hide-large" style="float:right;border-width:0;display:block;margin-left:1em;padding:4px;"
			title="Show menus">
			<img src="/ct2/html/ct3/images/hamburgerMenuIcon.png" alt="ClinicalTrials.gov Menu" style="max-width:30px;cursor:pointer;" 
			 onclick="$('#global-nav-popupMenu').toggle();"/>
		</div>
		<div id="global-nav-popupMenu" class="w3-hide-medium w3-hide-large w3-modal w3-center" 
			 style="display:none;" onclick="$('#global-nav-popupMenu').hide();"> 			<div id="global-nav-popupMenu-content" class="w3-modal-content">
				<div class="w3-container">
				    <span onclick="$('#global-nav-popupMenu').hide();"
				      class="w3-closebtn">&times;</span>
					<ul class="sf-menu sf-vertical">
									<li class="first"><a href="/ct2/search/index">Find Studies<img src="/ct2/html/ct3/images/pulldown.png" alt="Find Studies Menu"></a>
			<ul>
                      <li                  ><a                  href="/ct2/home">New Search</a></li>
                      <li                  ><a         href="/ct2/search/advanced">Advanced Search</a></li>
                      <li                  ><a     href="/ct2/search/browse?brwse=cond_cat">See Studies by Topic</a></li>
                      <li                  ><a             href="/ct2/search/map">See Studies on Map</a></li>
                      <li class="new-group"><a           href="/ct2/help/how-find/index">How to Search</a></li>
                      <li                  ><a href="/ct2/help/how-use-search-results">How to Use Search Results</a></li>
                      <li                  ><a        href="/ct2/help/how-find/find-study-results">How to Find Results of Studies</a></li>
                      <li                  ><a          href="/ct2/help/how-read-study">How to Read a Study Record</a></li>
			</ul>
			</li>
			<li><a href="/ct2/about-studies">About Studies<img src="/ct2/html/ct3/images/pulldown.png" alt="About Studies Menu"></a>
			<ul>
                      <li><a href="/ct2/about-studies/learn">Learn About Studies</a></li>
                      <li><a  href="/ct2/about-studies/other-sites">Other Sites About Studies</a></li>
                      <li><a         href="/ct2/about-studies/glossary">Glossary of Common Site Terms</a></li>
			</ul>
			</li>
			<li><a href="/ct2/manage-recs">Submit Studies<img src="/ct2/html/ct3/images/pulldown.png" alt="Submit Studies Menu"></a>
			<ul>
                      <li><a                          href="/ct2/manage-recs/background">Why Should I Register and Submit Results?</a></li>
                      <li><a                                href="/ct2/manage-recs/fdaaa">FDAAA 801 Requirements</a></li>
                      <li class="new-group"><a    href="/ct2/manage-recs/how-apply">How to Apply for an Account</a></li>
                      <li><a                        href="/ct2/manage-recs/how-register">How to Register Your Study</a></li>
                      <li><a                         href="/ct2/manage-recs/how-edit">How to Edit Your Study Record</a></li>
                      <li><a                   href="/ct2/manage-recs/how-report">How to Submit Your Results</a></li>
                      <li class="new-group"><a       href="/ct2/manage-recs/faq">Frequently Asked Questions</a></li>
                      <li                  ><a href="/ct2/manage-recs/resources">Support Materials</a></li>
                      <li                  ><a      href="/ct2/manage-recs/present">Training Materials</a></li>
			</ul>
			</li>
			<li><a href="/ct2/resources">Resources<img src="/ct2/html/ct3/images/pulldown.png" alt="Resources Menu"></a>
			<ul>
                      <li                  ><a    href="/ct2/resources/pubs">Selected Publications</a></li>
                      <li                  ><a       href="/ct2/resources/alert">Clinical Alerts and Advisories</a></li>
                      <li                  ><a     href="/ct2/resources/rss">RSS Feeds</a></li>
                      <li class="new-group"><a href="/ct2/resources/trends">Trends, Charts, and Maps</a></li>
                      <li                  ><a   href="/ct2/resources/download">Downloading Content for Analysis</a></li>
			</ul>
			</li>
			<li class="last"><a href="/ct2/about-site">About Site<img src="/ct2/html/ct3/images/pulldown.png" alt="About Site Menu"></a>
			<ul>
                      <li class="new-group"><a href="/ct2/about-site/background">ClinicalTrials.gov Background</a></li>
                      <li                  ><a    href="/ct2/about-site/results">About the Results Database</a></li>
                      <li                  ><a    href="/ct2/about-site/history">History, Policies, and Laws</a></li>
                      <li                  ><a   href="/ct2/about-site/for-media">Media/Press Resources</a></li>
                      <li class="new-group"><a          href="/ct2/about-site/link-to">Linking to This Site</a></li>
                      <li                  ><a           href="/ct2/about-site/terms-conditions">Terms and Conditions</a></li>
                      <li                  ><a      href="/ct2/about-site/disclaimer">Disclaimer</a></li>
			</ul>
			</li>
					</ul>
				</div>
    		</div>
  		</div>		

	  	<div id="savedStudies" style="float:right;padding:4px 8px;"> 		  	<div id="cart" style="cursor:pointer;" onclick="location.href=('/ct2/results'+cartToURL()); showWorking();">
		  	<button class="savedStudiesEnabled" id="open-cart-link" type="button" 
		  		onclick="location.href=('/ct2/results'+cartToURL()); showWorking();"
		  		title="Show previously saved studies.">Saved Studies</button>
		  	</div>
			<button class="savedStudiesDisabled" id="cart-disabled" type="button" disabled
				title="There are no saved studies to show. You can save studies to visit later from the search results page">Saved Studies (0)</button>
		</div>

		<div style="clear:right;text-align:right;padding-top:1ex;padding-right:8px;font-size:small;">
			<a href="https://survey.foreseeresults.com/survey/display?cid=WyHFr2m0PoaGCBUsi00QIQ==&sid=link-ct" target="_blank">Give us feedback</a></div>
		<script type="text/javascript" src="/ct2/html/ct3/js/cart.js?v=b4"></script><noscript></noscript>
  	
<div id="global-nav" class="w3-hide-small">
	<ul class="sf-menu sf-vertical">
			<li class="first"><a href="/ct2/search/index">Find Studies<img src="/ct2/html/ct3/images/pulldown.png" alt="Find Studies Menu"></a>
			<ul>
                      <li                  ><a                  href="/ct2/home">New Search</a></li>
                      <li                  ><a         href="/ct2/search/advanced">Advanced Search</a></li>
                      <li                  ><a     href="/ct2/search/browse?brwse=cond_cat">See Studies by Topic</a></li>
                      <li                  ><a             href="/ct2/search/map">See Studies on Map</a></li>
                      <li class="new-group"><a           href="/ct2/help/how-find/index">How to Search</a></li>
                      <li                  ><a href="/ct2/help/how-use-search-results">How to Use Search Results</a></li>
                      <li                  ><a        href="/ct2/help/how-find/find-study-results">How to Find Results of Studies</a></li>
                      <li                  ><a          href="/ct2/help/how-read-study">How to Read a Study Record</a></li>
			</ul>
			</li>
			<li><a href="/ct2/about-studies">About Studies<img src="/ct2/html/ct3/images/pulldown.png" alt="About Studies Menu"></a>
			<ul>
                      <li><a href="/ct2/about-studies/learn">Learn About Studies</a></li>
                      <li><a  href="/ct2/about-studies/other-sites">Other Sites About Studies</a></li>
                      <li><a         href="/ct2/about-studies/glossary">Glossary of Common Site Terms</a></li>
			</ul>
			</li>
			<li><a href="/ct2/manage-recs">Submit Studies<img src="/ct2/html/ct3/images/pulldown.png" alt="Submit Studies Menu"></a>
			<ul>
                      <li><a                          href="/ct2/manage-recs/background">Why Should I Register and Submit Results?</a></li>
                      <li><a                                href="/ct2/manage-recs/fdaaa">FDAAA 801 Requirements</a></li>
                      <li class="new-group"><a    href="/ct2/manage-recs/how-apply">How to Apply for an Account</a></li>
                      <li><a                        href="/ct2/manage-recs/how-register">How to Register Your Study</a></li>
                      <li><a                         href="/ct2/manage-recs/how-edit">How to Edit Your Study Record</a></li>
                      <li><a                   href="/ct2/manage-recs/how-report">How to Submit Your Results</a></li>
                      <li class="new-group"><a       href="/ct2/manage-recs/faq">Frequently Asked Questions</a></li>
                      <li                  ><a href="/ct2/manage-recs/resources">Support Materials</a></li>
                      <li                  ><a      href="/ct2/manage-recs/present">Training Materials</a></li>
			</ul>
			</li>
			<li><a href="/ct2/resources">Resources<img src="/ct2/html/ct3/images/pulldown.png" alt="Resources Menu"></a>
			<ul>
                      <li                  ><a    href="/ct2/resources/pubs">Selected Publications</a></li>
                      <li                  ><a       href="/ct2/resources/alert">Clinical Alerts and Advisories</a></li>
                      <li                  ><a     href="/ct2/resources/rss">RSS Feeds</a></li>
                      <li class="new-group"><a href="/ct2/resources/trends">Trends, Charts, and Maps</a></li>
                      <li                  ><a   href="/ct2/resources/download">Downloading Content for Analysis</a></li>
			</ul>
			</li>
			<li class="last"><a href="/ct2/about-site">About Site<img src="/ct2/html/ct3/images/pulldown.png" alt="About Site Menu"></a>
			<ul>
                      <li class="new-group"><a href="/ct2/about-site/background">ClinicalTrials.gov Background</a></li>
                      <li                  ><a    href="/ct2/about-site/results">About the Results Database</a></li>
                      <li                  ><a    href="/ct2/about-site/history">History, Policies, and Laws</a></li>
                      <li                  ><a   href="/ct2/about-site/for-media">Media/Press Resources</a></li>
                      <li class="new-group"><a          href="/ct2/about-site/link-to">Linking to This Site</a></li>
                      <li                  ><a           href="/ct2/about-site/terms-conditions">Terms and Conditions</a></li>
                      <li                  ><a      href="/ct2/about-site/disclaimer">Disclaimer</a></li>
			</ul>
			</li>
	</ul>
    <div style="clear:both;"></div>
</div>
<div style="clear:both;"></div> 

<div id="utilities">
     
</div>
<div id="breadcrumb">
	<ul class="horz-list">
		<li><a href="/ct2/home">Home</a></li>
				<li class="last">Study Record Detail</li>
	</ul>
</div>


<div id="main-content">


        	<h1 class="solo_record">A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis</h1>
	<div id="trial-info-1" class="floater-50">

     


      
        <div  class="not-recruiting-status" >
      This study has been completed.
          </div>
        
        
      
        




                <div class="info-title">Sponsor:</div>
                <div class="info-text" id="sponsor"> AbbVie </div>



                              <div class="info-title">Information provided by (Responsible Party):</div>
                <div class="info-text">AbbVie</div>
              

            </div>
               <div id="trial-info-2" class="floater-50">
                <div class="info-title">ClinicalTrials.gov Identifier:</div>
                <div class="identifier">NCT02016482</div>
                <div class="info-date">First received: December 16, 2013</div>
                <div class="info-date">Last updated:  April 25, 2017</div>
                <div class="info-date">Last verified:  April 2017 </div>
                <div class="info-date"> <a href="/ct2/archive/NCT02016482"
          title="Historical versions of study NCT02016482 on ClinicalTrials.gov Archive Site - opens in new window"
          onclick="openNewWindow('/ct2/archive/NCT02016482'); return false;">History of Changes</a> </div>
            </div>



<div id="tabs">
        <ul id="tab-links">
			<li id="full-text" ><a href="/ct2/show/study/NCT02016482"  >Full Text View</a></li>
			<li id="tabular"     class="current"> Tabular View       </li>
			<li id="results"   ><a href="/ct2/show/results/NCT02016482">Study Results</a></li>
			<li id="disclaimer"><a href="/ct2/about-site/disclaimer">Disclaimer</a></li>
			<li id="howtoread"><a title="How to Read a Study Record - opens new window"  href="/ct2/help/how-read-study" onclick="openNewWindow('/ct2/help/how-read-study'); return false"
>How to Read a Study Record</a></li>
        </ul>
</div>  <div style="background-color:#f6f6f6;margin-top:3.5ex;padding-bottom:3.5ex;"> </div>




<!-- field list -->
<div class="indent1">
 
  <table class="w3-table data_table tableStyle">
    <tr>
      <th class="header2 banner_color sectionBanner" colspan="2">Tracking Information</th>
    </tr>
        <tr>
      <th class="header3 banner_color rowHeader">First Received Date&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">December 16, 2013</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Last Updated Date </th>
            <td class="body3 rowBody">April 25, 2017</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Start Date&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">January 2014</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Primary Completion Date </th>
            <td class="body3 rowBody">October 2015 &nbsp; (Final data collection date for primary outcome measure)</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Current Primary Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> <br/>&nbsp;<span class="footer">(submitted:&nbsp;December 21, 2016)</span></th>
            <td class="body3 rowBody"><ul style="margin:0ex 1em; padding:0ex 0em">
<li style="margin:1ex 0.5ex">Percentage of Participants Achieving a Total Fingernail Modified Nail Psoriasis Severity Index (mNAPSI) 75 Response at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">Each fingernail was assessed for psoriasis with mNAPSI, and the scores of all 10 fingernails were combined. Investigators assessed each nail abnormality for each of a participant&apos;s nails by grading 3 features or groups of features (pitting, onycholysis and oil-drop dyschromia, and crumbling) and noting the presence or absence of 4 features (leukonychia, splinter hemorrhages, hyperkeratosis, and red spots in the lunula). The range of possible scores was 0 to 130, with a score of 0 indicating absence of nail psoriasis and a score of 130 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement. The mNAPSI 75 response is defined as at least 75% reduction from baseline in mNAPSI.</div></li>
<li style="margin:1ex 0.5ex">For United States (US) Regulatory Purposes: Percentage of Participants With a Physician&apos;s Global Assessment of Fingernails (PGA-F) of &quot;Clear&quot; or &quot;Minimal&quot; at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">The PGA-F is a 5-point scale used to assess fingernails separately for nail bed signs and nail matrix signs of disease. A global score of between 0 indicating clear, and 4 indicating severe, was separately assigned for nail bed involvement and nail matrix involvement. A participant&apos;s overall global score was the worse of the nail bed and nail matrix score. Data presents the percentage of participants with a PGA-F overall global score that met the definition of &quot;clear&quot; (0) or &quot;minimal&quot; (1) with at least a 2-grade improvement relative to Baseline at Week 26.</div></li>
</ul>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Original Primary Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> <br/>&nbsp;<span class="footer">(submitted:&nbsp;December 16, 2013)</span></th>
            <td class="body3 rowBody"><ul style="margin:0ex 1em; padding:0ex 0em">
<li style="margin:1ex 0.5ex">Proportion of subjects achieving a total-fingernail modified Nail Psoriasis Severity Index (mNAPSI) 75 response [&nbsp;Time&nbsp;Frame:&nbsp;At Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">Subjects achieving a 75% reduction in total mNAPSI of all fingernails</div></li>
<li style="margin:1ex 0.5ex">Proportion of subjects with a Physician&apos;s Global Assessment of Fingernails of &quot;clear&quot; or &quot;minimal&quot; [&nbsp;Time&nbsp;Frame:&nbsp;At Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">Physician&apos;s assessment of patient&apos;s fingernails that meet definition of clear or minimal.</div></li>
</ul>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Change History </th>
            <td class="body3 rowBody"><a href="/ct2/archive/NCT02016482" onclick="openNewWindow('/ct2/archive/NCT02016482'); return false;">Complete list of historical versions of study NCT02016482 on ClinicalTrials.gov Archive Site</a></td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Current Secondary Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> <br/>&nbsp;<span class="footer">(submitted:&nbsp;December 21, 2016)</span></th>
            <td class="body3 rowBody"><ul style="margin:0ex 1em; padding:0ex 0em">
<li style="margin:1ex 0.5ex">Percent Change From Baseline in Total Fingernail Nail Psoriasis Severity Index (NAPSI) Score at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Baseline, Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">Each fingernail was assessed for nail matrix psoriasis and nail bed psoriasis with NAPSI and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 80, with a score of 0 indicating absence of nail psoriasis and 80 indicating most severe nail psoriasis. A decrease in NAPSI score indicates improvement.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants Achieving Total Fingernail mNAPSI Score of 0 at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">Each fingernail was assessed for psoriasis with mNAPSI, and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 130, with a score of 0 indicating absence of nail psoriasis and a score of 130 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.</div></li>
<li style="margin:1ex 0.5ex">Percent Change From Baseline in Nail Psoriasis Pain Numeric Rating Scale (NRS) at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Baseline, Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">An NRS was used to capture a participant&apos;s self-reporting of her/his worst fingernail pain and average fingernail pain due to fingernail psoriasis. The participant rated the severity of fingernail pain over the past 7 days on a scale from 0 indicating no pain, to 10 indicating severe pain. A negative change from Baseline indicates improvement.</div></li>
<li style="margin:1ex 0.5ex">Change From Baseline in Nail Psoriasis Physical Functioning Severity Score at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Baseline, Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">Participants were asked to rate the impact of their fingernail psoriasis on their ability to perform physical tasks (eg, typing, housework, buttoning a shirt or blouse, picking up coins from a table, tying shoes, yard work, etc.) over the past 7 days on a scale of 0 indicating no impact on ability to perform physical tasks, to 10 indicating severe impact on ability to perform physical tasks. A negative change from Baseline indicates improvement.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants With at Least 50% Improvement in the Scalp Component of the Brigham Scalp Nail Inverse Palmo-Plantar Psoriasis Index (B-SNIPI) at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Baseline, Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">The range of possible scores was 0 to 20 for scalp psoriasis, with a score of 0 indicating absence of psoriasis. A decrease in B-SNIPI score indicates improvement. Data presents the percentage of participants achieving 50% improvement in the scalp component of the B-SNIPI among participants with Baseline scalp score of &#8805; 6.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants Achieving &quot;Clear&quot; or &quot;Minimal&quot; in Nail Bed Component of the PGA-F at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">The PGA-F is a 5-point scale used to assess fingernails separately for nail bed signs and nail matrix signs of disease. A global score of between 0 indicating clear, and 4 indicating severe, was separately assigned for nail bed involvement and nail matrix involvement. A participant&apos;s overall global score was the worse of the nail bed and nail matrix score. Data presents the percentage of participants with a nail bed component of the PGA-F that met definition of &quot;clear&quot; (0) or &quot;minimal&quot; (1) among those with a Baseline nail bed component of &quot;moderate&quot; or &quot;worse.&quot;</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants Achieving &quot;Clear&quot; or &quot;Minimal&quot; in Nail Matrix Component of the PGA-F At Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">The PGA-F is a 5-point scale used to assess fingernails separately for nail bed signs and nail matrix signs of disease. A global score of between 0 indicating clear, and 4 indicating severe, was separately assigned for nail bed involvement and nail matrix involvement. A participant&apos;s overall global score was the worse of the nail bed and nail matrix score. Data presents the percentage of participants with a nail matrix component of the PGA-F that met definition of &quot;clear&quot; (0) or &quot;minimal&quot; (1) among those with a Baseline nail matrix component of &quot;moderate&quot; or &quot;worse.&quot;</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants Achieving Target Fingernail mNAPSI Score of 0 at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">The target fingernail was assessed for psoriasis with mNAPSI. The range of possible scores was 0 to 13, with a score of 0 indicating absence of nail psoriasis and a score of 13 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants Achieving Target Fingernail mNAPSI Score of &#8804; 2 at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">The target fingernail was assessed for psoriasis with mNAPSI. The range of possible scores was 0 to 13, with a score of 0 indicating absence of nail psoriasis and a score of 13 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants Achieving Total Fingernail mNAPSI Score of &#8804; 2 at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">Each fingernail was assessed for psoriasis with mNAPSI, and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 130, with a score of 0 indicating absence of nail psoriasis and a score of 130 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.</div></li>
<li style="margin:1ex 0.5ex">Change From Baseline in Target Fingernail mNAPSI Score at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Baseline, Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">The target fingernail was assessed for psoriasis with mNAPSI. The range of possible scores was 0 to 13, with a score of 0 indicating absence of nail psoriasis and a score of 13 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.</div></li>
<li style="margin:1ex 0.5ex">Percent Change From Baseline in Target Fingernail mNAPSI Score at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Baseline, Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">The target fingernail was assessed for psoriasis with mNAPSI. The range of possible scores was 0 to 13, with a score of 0 indicating absence of nail psoriasis and a score of 13 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.</div></li>
<li style="margin:1ex 0.5ex">Change From Baseline in Total Fingernail mNAPSI Score at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Baseline, Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">Each fingernail was assessed for psoriasis with mNAPSI, and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 130, with a score of 0 indicating absence of nail psoriasis and a score of 130 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.</div></li>
<li style="margin:1ex 0.5ex">Percent Change From Baseline in Total Fingernail mNAPSI Score at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Baseline, Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">Each fingernail was assessed for psoriasis with mNAPSI, and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 130, with a score of 0 indicating absence of nail psoriasis and a score of 130 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants Achieving Total Fingernail NAPSI Score of 0 at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">Each fingernail was assessed for nail matrix psoriasis and nail bed psoriasis with NAPSI and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 80, with a score of 0 indicating absence of nail psoriasis and 80 indicating most severe nail psoriasis. A decrease in NAPSI score indicates improvement.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants Achieving Target Fingernail NAPSI Score of 0 at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">The target fingernail was assessed for nail matrix psoriasis and nail bed psoriasis with NAPSI. The range of possible scores was 0 to 8, with a score of 0 indicating absence of nail psoriasis and 8 indicating most severe nail psoriasis. A decrease in NAPSI score indicates improvement.</div></li>
<li style="margin:1ex 0.5ex">Change From Baseline in Target Fingernail NAPSI Score at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Baseline, Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">The target fingernail was assessed for nail matrix psoriasis and nail bed psoriasis with NAPSI. The range of possible scores was 0 to 8, with a score of 0 indicating absence of nail psoriasis and 8 indicating most severe nail psoriasis. A decrease in NAPSI score indicates improvement.</div></li>
<li style="margin:1ex 0.5ex">Percent Change From Baseline in Target Fingernail NAPSI Score at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Baseline, Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">The target fingernail was assessed for nail matrix psoriasis and nail bed psoriasis with NAPSI. The range of possible scores was 0 to 8, with a score of 0 indicating absence of nail psoriasis and 8 indicating most severe nail psoriasis. A decrease in NAPSI score indicates improvement.</div></li>
<li style="margin:1ex 0.5ex">Change From Baseline in Total Fingernail NAPSI Score at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Baseline, Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">Each fingernail was assessed for nail matrix psoriasis and nail bed psoriasis with NAPSI and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 80, with a score of 0 indicating absence of nail psoriasis and 80 indicating most severe nail psoriasis. A decrease in NAPSI score indicates improvement.</div></li>
<li style="margin:1ex 0.5ex">Change From Baseline in Psoriasis Area Severity Index (PASI) Score at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Baseline, Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 to 72, with 0 indicating no psoriasis and 72 indicating very severe psoriasis. A decrease in PASI score indicates improvement.</div></li>
<li style="margin:1ex 0.5ex">Percent Change From Baseline in PASI Score at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Baseline, Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 to 72, with 0 indicating no psoriasis and 72 indicating very severe psoriasis. A decrease in PASI score indicates improvement.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants Achieving PASI 75/50/90/100 Responses at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 to 72, with 0 indicating no psoriasis and 72 indicating very severe psoriasis. PASI-75, 50, 90, and 100 responses are the percentage of participants with a Baseline PASI score &#8805; 5 who achieved at least a 75%, 50%, 90%, or 100% reduction (improvement), respectively, from Baseline in PASI score at Week 26. A 100% reduction was considered complete clearance of psoriasis. Data presents the percentage of participants achieving PASI 75/50/90/100 responses at Week 26 among participants with a Baseline PASI score &#8805; 5.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants Achieving Physician&apos;s Global Assessment of Skin Psoriasis (PGA-S) &quot;Clear&quot; or &quot;Minimal&quot; at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">The PGA-S is a 6-point scale used to measure the severity of skin disease at the time of the qualified investigator&apos;s evaluation of the participant. The degree of overall lesion severity was assessed, with 0 indicating cleared and 5 indicating severe. A decrease in PGA-S score indicates improvement. Data present the percentage of participants achieving a PGA-S of &quot;clear&quot; (0) or &quot;minimal&quot; (1) with at least a 2-grade improvement relative to Baseline at Week 26.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants Achieving PGA-S of &quot;Clear&quot; at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">The PGA-S is a 6-point scale used to measure the severity of skin disease at the time of the qualified investigator&apos;s evaluation of the participant. The degree of overall lesion severity was assessed, with 0 indicating cleared and 5 indicating severe. A decrease in PGA-S score indicates improvement. Data present the percentage of participants achieving a PGA-S of &quot;clear&quot; (0) with at least a 2-grade improvement relative to Baseline at Week 26.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants Achieving 50% Improvement in the Inverse Psoriasis Component of the B-SNIPI at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">The range of possible B-SNIPI scores was 0 to 20 for inverse psoriasis, with a score of 0 indicating absence of psoriasis and a score of 20 indicating most severe psoriasis. A decrease in B-SNIPI score indicates improvement. Data presents the percentage of participants achieving 50% improvement in the inverse component of the B-SNIPI among participants with a Baseline inverse psoriasis score of &#8805; 6.</div></li>
<li style="margin:1ex 0.5ex">Change From Baseline in Total Body Surface Area (BSA) at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Baseline, Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">BSA affected by psoriasis was measured by the physician selecting the participant&apos;s right or left hand as the measuring device. For purposes of clinical estimation, the total surface of the palm plus 5 digits was to be assumed to be approximately equivalent to 1% BSA. Measurement of the total area of involvement by the physician was aided by imagining if scattered plaques were moved so that they were next to each other and then estimated the total area involved. A decrease in BSA affected by psoriasis indicates improvement.</div></li>
<li style="margin:1ex 0.5ex">Percent Change From Baseline in Total BSA at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Baseline, Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">BSA affected by psoriasis was measured by the physician selecting the participant&apos;s right or left hand as the measuring device. For purposes of clinical estimation, the total surface of the palm plus 5 digits was to be assumed to be approximately equivalent to 1% BSA. Measurement of the total area of involvement by the physician was aided by imagining if scattered plaques were moved so that they were next to each other and then estimated the total area involved. A decrease in BSA affected by psoriasis indicates improvement.</div></li>
<li style="margin:1ex 0.5ex">Percent Change From Baseline in Nail Psoriasis Pain NRS at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Baseline, Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">An NRS was used to capture a participant&apos;s self-reporting of her/his worst fingernail pain and average fingernail pain due to fingernail psoriasis. The participant rated the severity of fingernail pain over the past 7 days on a scale from 0 indicating no pain, to 10 indicating severe pain. A negative change from Baseline indicates improvement.</div></li>
<li style="margin:1ex 0.5ex">Percent Change From Baseline in Nail Psoriasis Physical Functioning Severity Score at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Baseline, Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">Participants were asked to rate the impact of their fingernail psoriasis on their ability to perform physical tasks (eg, typing, housework, buttoning a shirt or blouse, picking up coins from a table, tying shoes, yard work, etc.) over the past 7 days on a scale of 0 indicating no impact on ability to perform physical tasks, to 10 indicating severe impact on ability to perform physical tasks. A negative change from Baseline indicates improvement.</div></li>
<li style="margin:1ex 0.5ex">Change From Baseline in Nail Assessment in Psoriasis and Psoriatic Arthritis Quality of Life (NAPPA QoL) at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Baseline, Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">Participants rated specific impacts of fingernail psoriasis on various aspects of their QoL over the past 7 days on a 5-point scale, with 0 indicating not at all, and 4 indicating very impactful. A participant&apos;s overall global score was the mean of all items and could range from 0 to 4, with 0 indicating no impact and 4 indicating most impact. A decrease in NAPPA QoL score indicates improvement.</div></li>
<li style="margin:1ex 0.5ex">Percent Change From Baseline in Nail Assessment in NAPPA QoL at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Baseline, Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">Participants rated specific impacts of fingernail psoriasis on various aspects of their QoL over the past 7 days on a 5-point scale, with 0 indicating not at all, and 4 indicating very impactful. A participant&apos;s overall global score was the mean of all items and could range from 0 to 4, with 0 indicating no impact and 4 indicating most impact. A decrease in NAPPA QoL score indicates improvement.</div></li>
<li style="margin:1ex 0.5ex">Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Baseline, Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">Participants assessed symptoms and impacts of dermatologic diseases on their QoL over the past 7 days, with 0 indicating not at all, and 3 indicating very much. The range of possible DLQI scores was 0 to 30, with a score of 0 indicating no effect at all on a participant&apos;s life and a score of 30 indicating extremely large effect on participant&apos;s life. A decrease in DLQI score indicates improvement.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants Achieving DLQI of 0 and 0/1 at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">Participants assessed symptoms and impacts of dermatologic diseases on their QoL over the past 7 days, with 0 indicating not at all, and 3 indicating very much. The range of possible DLQI scores was 0 to 30, with a score of 0 indicating no effect at all on a participant&apos;s life and a score of 30 indicating extremely large effect on participant&apos;s life. A decrease in DLQI score indicates improvement. Data presents the percentage of participants with a score of 0 (no effect) or 1 (little effect) at Week 26.</div></li>
<li style="margin:1ex 0.5ex">Change From Baseline in Work Productivity and Activity Impairment Nail Psoriasis (WPAI:NPSO) at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Baseline, Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">The WPAI: NPSO assessed impact of fingernail psoriasis on work productivity and non-work activity limitation. Participants were asked during the past 7 days, how many hours did you miss from work because of problems associated with your fingernail psoriasis (absenteeism), during the past seven days, how many hours did you miss from work because of any other reason, such as vacation, holidays, time off to participate in this study (presenteeism), how much did your fingernail psoriasis affect your productivity while you were working (overall work impairment), and much did your fingernail psoriasis affect your ability to do your regular daily activities, other than work at a job (activity impairment). Answers were rated on an 11-point scale, with 0 indicating &quot;fingernail psoriasis had no effect on this&quot; and 10 indicating &quot;fingernail psoriasis completely prevented me from this.&quot; A decrease in the WPAI:NPSO score indicates improvement.</div></li>
<li style="margin:1ex 0.5ex">Change From Baseline in EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) Health State Assessment at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Baseline, Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">The EQ-5D-5L descriptive system comprises 5 dimensions of health (mobility, self -care, usual activities, pain/discomfort, and anxiety/depression) to describe the subject&apos;s current health state. Each dimension comprises 5 levels with corresponding numeric scores, where 1 indicates no problems, and 5 indicates extreme problems. A unique EQ-5D-5L health state is defined by combining the numeric level scores for each of the 5 dimensions and the total score is normalized from -0.594 to 1.000, with higher scores representing a better health state. An increase in the EQ-5D-5L total score indicates improvement.</div></li>
<li style="margin:1ex 0.5ex">Change From Baseline in EQ-5D Visual Analogue Scale (VAS) at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Baseline, Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">The EQ-5D VAS records the participant&apos;s self-rated health status on a vertical graduated scale from 0 to 100, with 0 indicating the worst imaginable health state and 100 indicating the best imaginable health state. An increase in EQ-5D-5L VAS score indicates improvement.</div></li>
<li style="margin:1ex 0.5ex">Change From Baseline in Hospital Anxiety Depression Scale (HADS) at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Baseline, Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">Participants rated their anxiety and depression over the past 7 days at Week 26. The range of possible scores was 0 to 21, with a score of 0 indicating absence of anxiety and depression and 21 indicating the most severe anxiety and depression. A decrease in HADS score indicates improvement.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants With a New Diagnosis of Psoriatic Arthritis (PsA) During the Study [&nbsp;Time&nbsp;Frame:&nbsp;up to Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">The percentage of participants with a new diagnosis of PsA (ie, with an adverse event of PsA) during the study, among participants without PsA at Baseline.</div></li>
<li style="margin:1ex 0.5ex">Change From Baseline in Nail Psoriasis Quality of Life (Nail PsQoL) Score at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Baseline, Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">Participants were asked how their fingernail psoriasis impacted their overall quality of life over the past 7 days on an 11-point scale, with 0 indicating no impact, and 10 indicating severe impact. A negative change from Baseline indicates improvement.</div></li>
</ul>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Original Secondary Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> <br/>&nbsp;<span class="footer">(submitted:&nbsp;December 16, 2013)</span></th>
            <td class="body3 rowBody"><ul style="margin:0ex 1em; padding:0ex 0em">
<li style="margin:1ex 0.5ex">Percent change in total mNAPSI of all fingernails [&nbsp;Time&nbsp;Frame:&nbsp;From Week 0 to Week 26&nbsp;]</li>
<li style="margin:1ex 0.5ex">Proportion of subjects achieving mNAPSI = 0 in all fingernails [&nbsp;Time&nbsp;Frame:&nbsp;At Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">Subjects who achieve a mNAPSI score of 0</div></li>
<li style="margin:1ex 0.5ex">Change in Nail Psoriasis Pain Numeric Rating Scale (NRS) [&nbsp;Time&nbsp;Frame:&nbsp;From Week 0 to Week 26&nbsp;]</li>
<li style="margin:1ex 0.5ex">Change in Nail Psoriasis Physical Functioning Severity Score [&nbsp;Time&nbsp;Frame:&nbsp;From Week 0 to Week 26&nbsp;]</li>
<li style="margin:1ex 0.5ex">Change in Nail Assessment in Psoriasis and Psoriatic Arthritis Quality of Life (NAPPA QoL) [&nbsp;Time&nbsp;Frame:&nbsp;From Week 0 to Week 26&nbsp;]</li>
</ul>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Current Other Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="missing_color">Not Provided</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Original Other Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> <br/>&nbsp;<span class="footer">(submitted:&nbsp;December 16, 2013)</span></th>
            <td class="body3 rowBody"><ul style="margin:0ex 1em; padding:0ex 0em">
<li style="margin:1ex 0.5ex">Proportion of subjects achieving a total-fingernail mNAPSI 75 response [&nbsp;Time&nbsp;Frame:&nbsp;At Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">Proportion of subjects with a 75% improvement in mNAPSI score</div></li>
<li style="margin:1ex 0.5ex">Proportion of subjects achieving PGA-F of &quot;clear&quot; or &quot;minimal&quot; [&nbsp;Time&nbsp;Frame:&nbsp;At Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">Physician&apos;s assessment of patient&apos;s fingernails that meet definition of clear or minimal.</div></li>
<li style="margin:1ex 0.5ex">Proportion of subjects achieving &quot;clear&quot; or &quot;minimal&quot; in nail bed component of the PGA-F, among those with a nail bed component of &quot;moderate&quot; or worse. [&nbsp;Time&nbsp;Frame:&nbsp;At Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">Physician&apos;s assessment of patient&apos;s fingernails that meet definition of clear or minimal among those with a nail bed component of &quot;moderate&quot; for worse.</div></li>
<li style="margin:1ex 0.5ex">Proportion of subjects achieving &quot;clear&quot; or &quot;minimal&quot; in nail matrix component of the PGA-F, among those with a nail matrix component of &quot;moderate&quot; or worse. [&nbsp;Time&nbsp;Frame:&nbsp;At Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">Physician&apos;s assessment of patient&apos;s fingernails that meet definition of clear or minimal among those with a nail matrix component of &quot;moderate&quot; or worse.</div></li>
<li style="margin:1ex 0.5ex">Proportion of subjects achieving mNAPSI = 0 in target fingernail. [&nbsp;Time&nbsp;Frame:&nbsp;At Week 26&nbsp;]</li>
<li style="margin:1ex 0.5ex">Proportion of subjects achieving mNAPSI = 0 of all fingernails [&nbsp;Time&nbsp;Frame:&nbsp;At Week 26&nbsp;]</li>
<li style="margin:1ex 0.5ex">Proportion of subjects achieving mNAPSI &#8804; 2 of the target fingernail [&nbsp;Time&nbsp;Frame:&nbsp;At Week 26&nbsp;]</li>
<li style="margin:1ex 0.5ex">Proportion of subjects achieving mNAPSI &#8804; 2 of all fingernails [&nbsp;Time&nbsp;Frame:&nbsp;At Week 26&nbsp;]</li>
<li style="margin:1ex 0.5ex">Change in mNAPSI of the target fingernail [&nbsp;Time&nbsp;Frame:&nbsp;From Week 0 to Week 26&nbsp;]</li>
<li style="margin:1ex 0.5ex">Change in mNAPSI score of all fingernails [&nbsp;Time&nbsp;Frame:&nbsp;From Week 0 to Week 26&nbsp;]</li>
<li style="margin:1ex 0.5ex">Proportion of subjects achieving NAPSI=0 in all fingernails [&nbsp;Time&nbsp;Frame:&nbsp;At Week 26&nbsp;]</li>
<li style="margin:1ex 0.5ex">Proportion of subjects achieving NAPSI=0 in target fingernail [&nbsp;Time&nbsp;Frame:&nbsp;At Week 26&nbsp;]</li>
<li style="margin:1ex 0.5ex">Change in total NAPSI of target fingernail [&nbsp;Time&nbsp;Frame:&nbsp;From Week 0 to Week 26&nbsp;]</li>
<li style="margin:1ex 0.5ex">Change in total NAPSI of all fingernails [&nbsp;Time&nbsp;Frame:&nbsp;From Week 0 to Week 26&nbsp;]</li>
<li style="margin:1ex 0.5ex">Change in Psoriasis Area Severity Index (PASI) [&nbsp;Time&nbsp;Frame:&nbsp;From Week 0 to Week 26&nbsp;]</li>
<li style="margin:1ex 0.5ex">Proportion of subjects achieving total PASI 75/50/90/100 among subjects with PASI score &#8805; 5 [&nbsp;Time&nbsp;Frame:&nbsp;At Week 26&nbsp;]</li>
<li style="margin:1ex 0.5ex">Proportion of subjects achieving physician&apos;s global assessment of skin psoriasis (PGA-S) &quot;clear&quot; or &quot;minimal&quot; [&nbsp;Time&nbsp;Frame:&nbsp;At Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">Physician&apos;s assessment of patient&apos;s skin psoriasis that meets definition of clear or minimal</div></li>
<li style="margin:1ex 0.5ex">Change in total body surface area (BSA) [&nbsp;Time&nbsp;Frame:&nbsp;From Week 0 to Week 26&nbsp;]</li>
<li style="margin:1ex 0.5ex">Change in Nail Psoriasis Pain Numeric Rating Scale (NRS) [&nbsp;Time&nbsp;Frame:&nbsp;From Week 0 to Week 26&nbsp;]</li>
<li style="margin:1ex 0.5ex">Change in Nail Psoriasis Physical Functioning Severity Score [&nbsp;Time&nbsp;Frame:&nbsp;From Week 0 to Week 26&nbsp;]</li>
<li style="margin:1ex 0.5ex">Change in Nail Assessment in Psoriasis and Psoriatic Arthritis Quality of Life (NAPPA QoL) [&nbsp;Time&nbsp;Frame:&nbsp;From Week 0 to Week 26&nbsp;]</li>
<li style="margin:1ex 0.5ex">Change in dermatology life quality index (DLQI) [&nbsp;Time&nbsp;Frame:&nbsp;From Week 0 to Week 26&nbsp;]</li>
<li style="margin:1ex 0.5ex">Proportion of subjects achieving DLQI of 0, and achieving DLQI of 0/1 [&nbsp;Time&nbsp;Frame:&nbsp;At Week 26&nbsp;]</li>
<li style="margin:1ex 0.5ex">Change in Work Productivity and Activity Impairment Nail Psoriasis (WPAI:NPSO) [&nbsp;Time&nbsp;Frame:&nbsp;From Week 0 to Week 26&nbsp;]</li>
<li style="margin:1ex 0.5ex">Change in EuroQol-5Dimensions-5Levels (EQ-5D-5L) Health Status Assessment [&nbsp;Time&nbsp;Frame:&nbsp;From Week 0 to Week 26&nbsp;]</li>
<li style="margin:1ex 0.5ex">Change in Hospital Anxiety Depression Scale (HADS) [&nbsp;Time&nbsp;Frame:&nbsp;From Week 0 to Week 26&nbsp;]</li>
<li style="margin:1ex 0.5ex">Proportion of subjects with a new diagnosis of psoriatic arthritis (PsA) during the study (with adverse event of PsA) among subjects without PsA. [&nbsp;Time&nbsp;Frame:&nbsp;At Week 26&nbsp;]</li>
<li style="margin:1ex 0.5ex">Change in Nail Psoriasis Quality of Life (Nail PsQoL) [&nbsp;Time&nbsp;Frame:&nbsp;From Week 0 to Week 26&nbsp;]</li>
<li style="margin:1ex 0.5ex">Percent change in mNAPSI of the target fingernail [&nbsp;Time&nbsp;Frame:&nbsp;From Week 0 to Week 26&nbsp;]</li>
<li style="margin:1ex 0.5ex">Percent change in mNAPSI score of all fingernails [&nbsp;Time&nbsp;Frame:&nbsp;From Week 0 to Week 26&nbsp;]</li>
<li style="margin:1ex 0.5ex">Percent change in total NAPSI of target fingernail [&nbsp;Time&nbsp;Frame:&nbsp;From Week 0 to Week 26&nbsp;]</li>
<li style="margin:1ex 0.5ex">Percent change in total NAPSI of all fingernails [&nbsp;Time&nbsp;Frame:&nbsp;From Week 0 to Week 26&nbsp;]</li>
<li style="margin:1ex 0.5ex">Percent change in Psoriasis Area Severity Index (PASI) of all fingernails [&nbsp;Time&nbsp;Frame:&nbsp;From Week 0 to Week 26&nbsp;]</li>
<li style="margin:1ex 0.5ex">Percent change in total body surface area (BSA) [&nbsp;Time&nbsp;Frame:&nbsp;From Week 0 to Week 26&nbsp;]</li>
<li style="margin:1ex 0.5ex">Percent change in Nail Psoriasis Pain Numeric Rating Scale (NRS) [&nbsp;Time&nbsp;Frame:&nbsp;From Week 0 to Week 26&nbsp;]</li>
<li style="margin:1ex 0.5ex">Percent change in Nail Psoriasis Physical Functioning Severity Score [&nbsp;Time&nbsp;Frame:&nbsp;From Week 0 to Week 26&nbsp;]</li>
<li style="margin:1ex 0.5ex">Percent change in Nail Assessment in Psoriasis and Psoriatic Arthritis Quality of Life (NAPPA QoL) [&nbsp;Time&nbsp;Frame:&nbsp;From Week 0 to Week 26&nbsp;]</li>
</ul>
</td>
          </tr>
    
    <tr><td colspan=2>&nbsp;</td></tr>

    <tr>
      <th class="header2 banner_color sectionBanner" colspan="2">Descriptive Information</th>
    </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Brief Title&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Official Title&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">A Phase 3, Multicenter, Double-Blind, Randomized, Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Patients With Chronic Plaque Psoriasis</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Brief Summary </th>
            <td class="body3 rowBody">This study is being conducted to assess the safety and efficacy of adalimumab in participants with nail psoriasis.</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Detailed Description </th>
            <td class="missing_color">Not Provided</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Study Type&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Interventional</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Study Phase </th>
            <td class="body3 rowBody">Phase 3</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Study Design&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Allocation: Randomized<br/>Intervention Model: Parallel Assignment<br/>Masking: Participant, Investigator<br/>Primary Purpose: Treatment</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Condition&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody"><ul style="margin:0ex 1em; padding:0ex 0em">
<li style="margin:1ex 0.5ex">Nail Psoriasis</li>
<li style="margin:1ex 0.5ex">Plaque Psoriasis</li>
</ul>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Intervention&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody"><ul style="margin:0ex 1em; padding:0ex 0em">
<li style="margin:1ex 0.5ex">Biological: Adalimumab
<div class="indent2" style="margin-top:0.5ex">Other Names:<ul style="margin-top:0.5ex">
<li>ABT-D2E7</li>
<li>Humira</li>
</ul>
</div></li>
<li style="margin:1ex 0.5ex">Other: Placebo</li>
</ul>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Study Arms </th>
            <td class="body3 rowBody"><ul style="margin:0ex 1em; padding:0ex 0em">
<li style="margin:1ex 0.5ex">Active Comparator: Adalimumab (ADA)
<div class="indent2" style="margin-top:0.5ex">Period A: ADA 40 mg subcutaneous every other week (sc eow) for 25 weeks starting 1 week after initial loading dose of 80 mg. Period B: Placebo at Week 26 followed by ADA 40 mg sc eow from Week 27 through Week 51.</div>
<div class="indent2" style="margin-top:0.5ex">Interventions:<ul style="margin-top:0.5ex">
<li>Biological: Adalimumab</li>
<li>Other: Placebo</li>
</ul>
</div></li>
<li style="margin:1ex 0.5ex">Placebo Comparator: Placebo
<div class="indent2" style="margin-top:0.5ex">Period A: Placebo sc eow for 25 weeks. Period B: ADA 80 mg sc at Week 26 followed by ADA 40 mg sc eow from Week 27 through Week 51.</div>
<div class="indent2" style="margin-top:0.5ex">Interventions:<ul style="margin-top:0.5ex">
<li>Biological: Adalimumab</li>
<li>Other: Placebo</li>
</ul>
</div></li>
</ul>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Publications * </th>
            <td class="missing_color">Not Provided</td>
          </tr>
    
    <tr>
      <td class="header3" style="padding-left:2em" colspan="2">
        <br/>
        * &nbsp; Includes publications given by the data provider as well as publications
        identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
      </td>
    </tr>

    <tr><td colspan=2>&nbsp;</td></tr>

    <tr>
      <th class="header2 banner_color sectionBanner" colspan="2">Recruitment Information</th>
    </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Recruitment Status&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Completed</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Enrollment&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">217</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Completion Date </th>
            <td class="body3 rowBody">April 2016</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Primary Completion Date </th>
            <td class="body3 rowBody">October 2015 &nbsp; (Final data collection date for primary outcome measure)</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Eligibility Criteria&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody"><p style="margin-top:1ex; margin-bottom:1ex;">Inclusion Criteria:</p>
  <ul style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">Subject must have body surface area (BSA) &#8805; 10% and a target fingernail Modified Nail Psoriasis Severity Index (mNAPSI) &#8805; 8 at Week 0, OR BSA &#8805; 5%, a target fingernail mNAPSI &#8805; 8 and a total mNAPSI score of &#8805; 20 at Week 0.</li>
    <li style="margin-top:0.7ex;">Subject must have a Nail Psoriasis Physical Functioning Severity score of &gt; 3, OR a Nail Psoriasis Pain Numeric Rating Scale (NRS) score of &gt;3.</li>
    <li style="margin-top:0.7ex;">Subjects must have a Physician's Global Assessment (PGA) of Fingernail Psoriasis and a PGA of Skin Psoriasis of at least moderate.</li>
    <li style="margin-top:0.7ex;">Subject must have discontinued use of all systemic therapies for the treatment of psoriasis, or systemic therapies known to improve psoriasis for at least 4 weeks prior to Week 0, ustekinumab must have been discontinued at least 12 weeks prior to Week 0.</li>
    <li style="margin-top:0.7ex;">Target fingernail must have mNAPSI score of &#8805; 8.</li>
    <li style="margin-top:0.7ex;">Adult subjects with clinical diagnosis of chronic plaque psoriasis (with disease duration of at least 6 months).</li>
  </ul>
  <p style="margin-top:0ex; margin-bottom:1ex;">Exclusion Criteria:</p>
  <ul style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">Prior adalimumab therapy.</li>
    <li style="margin-top:0.7ex;">Diagnosis of other active skin diseases or skin infections (bacterial, fungal, or viral) that may interfere with evaluation of skin or fingernail psoriasis.</li>
    <li style="margin-top:0.7ex;">Recent infection requiring treatment.</li>
    <li style="margin-top:0.7ex;">Significant medical events or conditions that may put patients at risk for participation, including recent history of drug or alcohol abuse.</li>
    <li style="margin-top:0.7ex;">Female subjects who are pregnant or breast-feeding or considering becoming pregnant during the study.</li>
    <li style="margin-top:0.7ex;">History of cancer, except successfully treated skin cancer.</li>
  </ul></td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Sex/Gender </th>
            <td class="body3 rowBody"><table class="layout_table" cellpadding="0" cellspacing="0" style="border:none;">
  <tr valign="top">
   <td style="padding:0px; margin:0ex; border:none;" nowrap>Sexes Eligible for Study:</td>
   <td style="padding:0px 0px 0px 1em; margin:0ex; border:none;">All</td>
  </tr>
</table>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Ages </th>
            <td class="body3 rowBody">18 Years to 99 Years &nbsp; (Adult, Senior)</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Accepts Healthy Volunteers </th>
            <td class="body3 rowBody">No</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Contacts&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody"><i style="color:#777777">Contact information is only displayed when the study is recruiting subjects</i></td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Listed Location Countries&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="missing_color">Not Provided</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Removed Location Countries </th>
            <td class="body3 rowBody">Australia, &nbsp; Belgium, &nbsp; Canada, &nbsp; France, &nbsp; Germany, &nbsp; Greece, &nbsp; Mexico, &nbsp; Puerto Rico, &nbsp; United States</td>
          </tr>
    
    <tr><td colspan=2>&nbsp;</td></tr>

    <tr>
      <th class="header2 banner_color sectionBanner" colspan="2">Administrative Information</th>
    </tr>
        <tr>
      <th class="header3 banner_color rowHeader">NCT Number&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">NCT02016482</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Other Study ID Numbers&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">M13-674<br> 2013-003275-36 ( EudraCT Number )</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Has Data Monitoring Committee </th>
            <td class="body3 rowBody">No</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">U.S. FDA-regulated Product </th>
            <td class="missing_color">Not Provided</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">IPD Sharing Statement </th>
            <td class="missing_color">Not Provided</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Responsible Party </th>
            <td class="body3 rowBody">AbbVie</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Study Sponsor&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">AbbVie</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Collaborators&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="missing_color">Not Provided</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Investigators&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody"><table class="layout_table" cellpadding="0" cellspacing="0" style="border:none;">
  <tr valign="top">
   <td style="padding:0px; margin:0ex; border:none;" nowrap>Study Director:</td>
   <td style="padding:0px 0px 0px 1em; margin:0ex; border:none;">David Williams, MD</td>
   <td style="padding:0px 0px 0px 1em; margin:0ex; border:none;">AbbVie</td>
  </tr>
</table>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">PRS Account </th>
            <td class="body3 rowBody">AbbVie</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Verification Date </th>
            <td class="body3 rowBody">April 2017</td>
          </tr>
    
    <tr>
      <td class="header3" style="padding-left:2em" colspan="2">
        <br/>
        <sup style="color:blue"> ICMJE </sup>&nbsp; &nbsp; Data element required by the
        <a href="http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html">
        International Committee of Medical Journal Editors</a> and the
        <a href="http://www.who.int/ictrp/network/trds/en/index.html">World Health Organization ICTRP</a>
      </td>
    </tr>

  </table>
</div>


<div id="to-top"><a href="#wrapper">To Top</a></div>

	<div style="clear:both;"></div>
</div> 

      <div id="for-footer">
        <ul class="horz-list">
            <li style="border-left:0;"><a    href="/ct2/help/for-patient">For Patients and Families</a></li>
            <li><a href="/ct2/help/for-researcher">For Researchers</a></li>
            <li><a     href="/ct2/help/for-manager">For Study Record Managers</a></li>
        </ul>
    </div>

<div id="footer-menu">
    <ul class="horz-list">
		<li><a href="/ct2/home" style="white-space:nowrap">Home</a></li>
		<li><a     href="/ct2/resources/rss" style="white-space:nowrap">RSS Feeds</a></li>
		<li><a         href="/ct2/sitemap" style="white-space:nowrap">Site Map</a></li>
		<li><a       href="/ct2/about-site/terms-conditions" style="white-space:nowrap">Terms and Conditions</a></li>
		<li><a href="/ct2/about-site/disclaimer" style="white-space:nowrap">Disclaimer</a></li>
		<li><a        href="https://support.nlm.nih.gov/ics/support/KBList.asp?folderID=146?style=classic&amp;deptID=28054&amp;category=clinicaltrials.gov&amp;hd_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2Frecord%2FNCT02016482" style="white-space:nowrap" onclick="openNewWindow('https://support.nlm.nih.gov/ics/support/KBList.asp?folderID=146?style=classic&amp;deptID=28054&amp;category=clinicaltrials.gov&amp;hd_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2Frecord%2FNCT02016482'); return false">Customer Support</a></li>
	</ul>
</div>

</div>  
<div id="fine-print">
	<ul class="horz-list">
		<li                  ><a title="NLM copyright information - opens new window"  href="https://www.nlm.nih.gov/copyright.html" onclick="openNewWindow('https://www.nlm.nih.gov/copyright.html'); return false"
>Copyright</a></li>
		<li                  ><a title="NLM privacy policy - opens new window"  href="https://www.nlm.nih.gov/privacy.html" onclick="openNewWindow('https://www.nlm.nih.gov/privacy.html'); return false"
>Privacy</a></li>
		<li                  ><a href="/ct2/accessibility" title="NLM Accessibility">Accessibility</a></li>
		<li                  ><a title="NLM viewers and players - opens new window"  href="https://www.nlm.nih.gov/plugins.html" onclick="openNewWindow('https://www.nlm.nih.gov/plugins.html'); return false"
>Viewers and Players</a></li>
		<li                  ><a title="NIH Freedom of Information Act office - opens new window"  href="https://www.nih.gov/icd/od/foia/index.htm" onclick="openNewWindow('https://www.nih.gov/icd/od/foia/index.htm'); return false"
>Freedom of Information Act</a></li>
		<li class="last-item"><a title="USA.gov - opens new window"  href="https://www.usa.gov/" onclick="openNewWindow('https://www.usa.gov/'); return false"
>USA.gov</a></li>
	</ul>
    <ul class="horz-list">
       <li><a title="U.S. National Library of Medicine - opens new window"  href="https://www.nlm.nih.gov/" onclick="openNewWindow('https://www.nlm.nih.gov/'); return false"
>U.S. National Library of Medicine</a></li>
       <li><a title="U.S. National Institutes of Health - opens new window"  href="https://www.nih.gov/" onclick="openNewWindow('https://www.nih.gov/'); return false"
>U.S. National Institutes of Health</a></li>
       <li class="last-item"><a title="U.S. Department of Health and Human Services - opens new window"  href="https://www.hhs.gov/" onclick="openNewWindow('https://www.hhs.gov/'); return false"
>
            U.S. Department of Health and Human Services</a></li>
    </ul>
</div>

    <script type="text/javascript" src="/ct2/html/ct3/js/instrumentNCBIBaseJS.min.js"></script><noscript></noscript>

</body>
</html>
